Kaiser Permanente Research Brief

Cardiovascular disease

This brief summarizes the contributions of Kaiser Permanente Research since 2007 on the topic of cardiovascular disease. Although CVD encompasses a wide array of health conditions, this brief will focus primarily on research related to stroke, coronary heart disease, and heart failure.

According to the Centers for Disease Control and Prevention, cardiovascular disease is responsible for nearly 700,000 deaths in the United States each year.¹ Though mostly preventable, it remains the leading cause of death in both men and women, and across nearly all racial and ethnic groups nationally.¹ Coronary heart disease, or the accumulation of atherosclerotic plaque within the arterial vessels of the heart, is the most common form of heart disease, and is associated with more than 380,000 deaths each year.¹ An estimated 6.2 million Americans also suffer from heart failure, or the heart’s inability to pump sufficient blood and oxygen to the body’s organ systems.² Heart failure is considered a contributing cause in approximately 1 in 9 deaths, and up to half of patients with heart failure may die within 5 years of diagnosis.² Stroke, or a disruption in the blood supply to the brain caused by a burst or blocked blood vessel, occurs in nearly 800,000 Americans each year.³ Stroke kills approximately 140,000 Americans annually,⁴ and is a leading cause of significant long-term disability, with consequences that often require long-term skilled nursing care.³

Cardiovascular disease is an active area of study for Kaiser Permanente Research. Scientists across the organization have used our rich, comprehensive, longitudinal data to advance knowledge in the areas of understanding risk, improving patient outcomes, and translating research findings into policy and practice. We have published nearly 2,200 articles related to CVD since 2007.⁵ Together, these articles have been cited over 114,000 times. These articles are the product of observational studies,

Kaiser Permanente publications related to CVD since 2007

2,193 Journal articles
114,620 Citations
1,459 Citations in PubMed Guidelines

Source: Kaiser Permanente Publications Library and Scite metrics, as of November 17, 2022.
randomized controlled trials, meta-analyses, and other studies led by Kaiser Permanente scientists. Our unique environment – a fully integrated care and coverage model in which our research scientists, clinicians, medical groups, and health plan leaders collaborate – enables us to contribute important knowledge about CVD, and many other research topics.

**Understanding Risk**

**Who is at risk for developing cardiovascular disease?**

Kaiser Permanente scientists have assessed a variety of cardiovascular disease risk factors in adults, including diabetes, atrial fibrillation, high blood pressure, obesity, insulin resistance, kidney disease, HIV, infection with respiratory viruses, diet, physical activity, stressful life events and social isolation, environmental factors, biomarkers, age, race, and genetics. Our researchers have also studied CVD risk factors within pediatric populations, including challenges in the family environment, poor maternal cardiovascular health, congenital heart defects, high blood pressure, and obesity. Recent studies have also suggested that neighborhood and socioeconomic factors are implicated in the development of CVD.

In large part because of Kaiser Permanente’s emphasis on prevention, persistently high cholesterol and uncontrolled blood pressure are much less common among our members than in the broader U.S. population. In addition, the racial, ethnic, and socioeconomic disparities in these risk factors seen nationally are notably smaller among our members.

**What other health risks do people with cardiovascular disease face?**

People with CVD face several associated health risks. While death is a well-known consequence of many cardiovascular diseases, superior risk-factor control within Kaiser Permanente has reduced fatal and nonfatal CVD rates among our members. Nevertheless, CVD carries other significant risks, including cognitive decline, long-term disability, and the need for long-term post-acute care following stroke, repeated hospitalization among patients with heart failure, and dementia and diabetes among heart failure and coronary heart disease patients. Our scientists have highlighted the unique challenges the COVID-19 pandemic has posed for optimal management of cardiovascular illness.

Moreover, the medications used to treat various cardiovascular diseases carry significant risks and side effects. Patients receiving anticoagulants for prevention of stroke may be at increased risk of severe bleeding events, myocardial infarction, and death. In addition, common treatments for heart failure and high cholesterol, smoking, obesity, insulin resistance, kidney disease, HIV, infection with respiratory viruses, diet, physical activity, stressful life events and social isolation, environmental factors, biomarkers, age, race, and genetics. Our researchers have also studied CVD risk factors within pediatric populations, including challenges in the family environment, poor maternal cardiovascular health, congenital heart defects, high blood pressure, and obesity. Recent studies have also suggested that neighborhood and socioeconomic factors are implicated in the development of CVD.

In large part because of Kaiser Permanente’s emphasis on prevention, persistently high cholesterol and uncontrolled blood pressure are much less common among our members than in the broader U.S. population. In addition, the racial, ethnic, and socioeconomic disparities in these risk factors seen nationally are notably smaller among our members.

**Physical fitness insights**

Kaiser Permanente researchers have published important insights about physical fitness using data from CARDIA, a 30-year study of CVD risks and causes in 5,115 young adults in 4 U.S. cities.

Greater fitness in young adulthood is associated with superior heart function in middle age.

Short bursts of exercise (<10 minutes) can reduce the risk of high blood pressure.

Active commuting to work is associated with lower BMI, blood pressure, and cholesterol.

Walking or cycling to neighborhood amenities is associated with lower BMI and lower lifetime CVD risk.
Kaiser Permanente employs effective strategies to help patients with CVD

<table>
<thead>
<tr>
<th>Email</th>
<th>Telesroke</th>
<th>Refills by mail</th>
<th>Interactive voice response</th>
</tr>
</thead>
<tbody>
<tr>
<td>Email communication between physicians and patients with high blood pressure and/or diabetes was associated with improved performance scores.(^{202})</td>
<td>Rates of tissue plasminogen activator administration for acute stroke increased in emergency departments with an on-call neurologist available by phone.(^{286,287})</td>
<td>Patients enrolled in a mail-order pharmacy program were more likely to adhere to recommended hypertension treatment.(^{171})</td>
<td>In a randomized trial, statin adherence and cholesterol control were enhanced by IVR reminders.(^{251,255-258})</td>
</tr>
</tbody>
</table>

Blood pressure can have serious side effects, including high blood potassium,\(^{154}\) serious injuries from falls,\(^{155}\) and risk of birth defects.\(^{156}\)

### Improving Patient Outcomes

#### What are the key factors in effective treatment of people with cardiovascular disease?

**Risk-factor management:** In addition to direct treatment of CVD, ongoing risk-factor management is a critical component of the care of these patients. Studies conducted in Kaiser Permanente have found improved outcomes from smoking cessation interventions,\(^{187,188}\) dietary advice,\(^{188-197}\) and physical activity\(^{159;188,189;198-201}\) interventions in patients with CVD. Increased use of secure email between patients and clinicians has been associated with improved outcomes in patients with high blood pressure and diabetes.\(^{202}\) Other programs associated with improved risk factor control include self-monitoring in conjunction with counseling, education, and assistance with medication management.\(^{197;203-207}\) Disease management for heart failure patients in skilled nursing facilities,\(^{208,209}\) home-based cardiac

---

*April 2023 Kaiser Permanente Research Brief: Cardiovascular Disease*
CVD management

CVD management involves pharmacotherapy, risk factor control, and other secondary prevention.

Pharmacotherapy Directed by guidelines

Risk factor control
- Diet
- Weight management
- Smoking cessation
- Controlling blood pressure, glucose, and cholesterol

Secondary prevention
- Heart surgery or transplant
- Implantable defibrillators
- Stroke rehabilitation
- Cardiac rehabilitation

In several studies, Kaiser Permanente researchers found that the absence of appropriate treatment intensification was more common than medication nonadherence in CVD patients with uncontrolled risk factors.\textsuperscript{170;173;215,218;225,245}

<table>
<thead>
<tr>
<th>Uncontrolled risk factor</th>
<th>Non-adherence</th>
<th>Treatment not escalated</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood pressure</td>
<td>19% to 42%</td>
<td>26% to 78%</td>
</tr>
<tr>
<td>Blood sugar</td>
<td>18% to 42%</td>
<td>26% to 47%</td>
</tr>
<tr>
<td>Cholesterol</td>
<td>19% to 49%</td>
<td>25% to 55%</td>
</tr>
</tbody>
</table>

Pharmacotherapy: Medications are an established component of evidence-based care for both CVD management and control of risk factors. While a discussion of specific medications is beyond the scope of this brief, our researchers have led or collaborated on key studies exploring the efficacy and safety of numerous medications in CVD populations. These have included key studies of glucose-lowering medications for control of type 2 diabetes and prevention of cardiovascular complications of diabetes,\textsuperscript{173;174;212-216} drugs to lower blood pressure,\textsuperscript{85;217-228} and cholesterol-lowering medications,\textsuperscript{221,222,229,233} as well as recent studies of anticoagulant treatments for stroke prevention among patients with atrial fibrillation,\textsuperscript{152,234-237} and medications for acute heart failure.\textsuperscript{238-244}

Given its importance in the care of patients with CVD, medication adherence has also been a significant focus of research in Kaiser Permanente. Large cohort studies conducted by our scientists have found that nonadherence to medications such as ACE inhibitors, oral anticoagulants, statins, and beta-blockers is associated with increased risks for all-cause and cardiovascular mortality, revascularization (an invasive medical procedure that restores blood flow to blocked or narrowed coronary arteries), cardiovascular hospitalization, and other serious cardiovascular events.\textsuperscript{245-247} A large study of at-risk members starting statins found that 84% were still receiving them 1 year later, but only 42% had experienced no treatment gaps during that time.\textsuperscript{248} The trend of suboptimal preventive use of statins has proven difficult to reverse, as shown by a national-level study conducted by Kaiser Permanente scientists.\textsuperscript{249} Furthermore, patients at lower CVD risk are less likely to comply with prescribed statin therapy.\textsuperscript{250} We have evaluated several medication-adherence interventions for patients with CVD involving clinical pharmacist\textsuperscript{168,230,251,252} or community health worker\textsuperscript{253,254} outreach, interactive voice response calls and reporting,\textsuperscript{251,255-258} mail-order pharmacy programs,\textsuperscript{171} or web-based medication self-management.\textsuperscript{259} A
study conducted with our members who have diabetes found that addressing undertreatment in addition to nonadherence could significantly improve outcomes for people with uncontrolled blood glucose, cholesterol, or blood pressure.173

Other secondary prevention: In addition to medication and lifestyle modifications, surgical procedures (including heart transplantation) and device implantation are also components of CVD management in targeted patients. Coronary revascularization has been studied extensively within Kaiser Permanente. Our researchers have explored the adoption of this family of technologies and geographic variations in their use.261 Studies have found that improved patient outcomes are associated with the appropriate use of specific invasive procedures,262-269 particular clinical characteristics,270;271 surgeons who perform more procedures272 and improved practices for managing blood clots.273

For patients with certain severe heart conditions, heart transplantation is an important treatment strategy. Our researchers have found that receiving a heart from a donor with diabetes mellitus,274 having a history of transplant rejection,275 and experiencing longer wait times before transplantation276 are associated with poorer heart transplant outcomes. Another study described a DNA-based method for noninvasive diagnosis of heart transplant rejection,277 increasing the ease of post-transplant monitoring. Our research on implantable cardiac defibrillator, or ICD, usage has explored how often these devices are used in off-label278;279 or non-guideline-directed fashion.280 Scientists at Kaiser Permanente have also found that preventive ICD implantation is not consistently performed in patients at high risk of sudden cardiac death.281 Other studies have found that mortality outcomes in patients with ICDs are associated with heart function, the heart’s structure,122 and higher BMI (body mass index),282 and have evaluated algorithms for the prediction of survival and sudden death in these patients.283;284

Translating Research Findings Into Policy and Practice

As part of a learning health care organization that uses research to inform and improve practice, Kaiser Permanente’s research, clinical, and operational partners have tested a range of interventions to reduce the risk of CVD and improve outcomes for patients with established CVD. For example, research supporting the efficacy of combining ACE inhibitors and thiazide diuretics in a single pill for blood pressure management and protocol-driven medication and dose adjustments222 led to broad adoption of these practices in Kaiser Permanente’s blood pressure management program.86 The spread of single-pill blood-pressure-lowering therapy also increased the ease of removing beta blockers as a first-line treatment, a transition prompted by our research data questioning the benefits of these medications.224 Our research in acute stroke management285 has led to implementation of effective telestroke programs with an on-call neurologist available via telemedicine technology to emergency department physicians in our Northern California286 and Southern California regions.287 More recently, our scientists have used artificial intelligence techniques to develop a risk prediction tool for

Heart attacks and high blood pressure rates

Thanks to interventions validated by our researchers, rates of heart attacks and high blood pressure dropped sharply in Kaiser Permanente Northern California between 1999 and 2014.

<table>
<thead>
<tr>
<th></th>
<th>1999</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>% with high blood pressure226</td>
<td>54%</td>
<td>10%</td>
</tr>
<tr>
<td>Heart attacks per 100,000 members103;104</td>
<td>274</td>
<td>185</td>
</tr>
</tbody>
</table>
patients entering the emergency department with acute heart failure. However, our work has also underscored many of the barriers to the use of similar risk calculators in primary care settings.

Collectively, research from Kaiser Permanente authors has been cited nearly 1,500 times within recent consensus statements and clinical practice guidelines published by a wide range of entities, including the American Stroke Association and American Heart Association. In addition, our researchers and clinician scientists have directly contributed as authors of 3 hypertension guidelines, as well as other guidelines published by the American College of Chest Physicians, the American College of Cardiology, the American Heart Association, and The Obesity Society, the American College of Cardiology and other societies, the American Heart Association, the Western Vascular Society, the Society for Vascular Surgery, the Lancet Commission on Hypertension, the American Academy of Neurology, the American College of Cardiology and other societies, the American Heart Association, the Western Vascular Society, the Society for Vascular Surgery, the Lancet Commission on Hypertension, the American Academy of Neurology, and the U.S. Preventive Services Task Force. Kaiser Permanente researchers have also taken part in the Implementation Science Work Group on CVD guidelines convened by the National Heart, Lung, and Blood Institute (NHLBI), a workshop on hypertension control sponsored by the NHLBI and the CDC, NHLBI workshops on research into heart failure and atrial fibrillation, an expert panel on cardiac rehabilitation for patients with heart failure, and the "Bending the Curve in Cardiovascular Disease Mortality" symposium sponsored by NHLBI and the American Heart Association. Our scientists have also participated in regional health collaboratives in the city of San Diego and in Sonoma County, California, aimed at reducing the burden of cardiovascular disease. Finally, the hypertension management efforts implemented in our California regions have received widespread recognition, particularly with respect to reducing racial disparities in blood pressure control.

Kaiser Permanente has shown considerable leadership in the field of CVD research. We have endorsed and actively supported the Department of Health and Human Services’ Million Hearts Initiative and our Colorado, Northern California, and Georgia regions have been recognized as Million Hearts Hypertension Control Champions. Kaiser Permanente has supported the care improvement efforts of safety net health care providers that operate in the same communities. Our researchers have led or collaborated on many notable studies related to epidemiology, prevention, risk factors, and treatment of CVD, including the Coronary Artery Risk Development in Young Adults (CARDIA) study, the Cardiovascular Research Network (CVRN), the Effectiveness of Gastric Bypass Versus Gastric Sleeve for Cardiovascular Disease (ENGAGE CVD) study, and the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study, all of which have been sponsored by the NIH’s National Heart, Lung, and Blood Institute.

Kaiser Permanente’s 185 research scientists and 1,530 support staff members are based at 9 research centers. There are currently 2,355 studies underway, including clinical trials. Since 2007, our research scientists and clinicians have published more than 19,000 articles. Kaiser Permanente currently serves more than 12.6 million members in 8 states and the District of Columbia.

This brief was written by Nicholas P. Emptage, Anna C. Davis, and Elizabeth A. McGlynn. It is available online from about.kaiserpermanente.org/health-and-wellness/health-research/research-briefs. The authors wish to thank the following researchers for their contributions to the development of this brief: Alan S. Go and Kristi Reynolds.
References


40. Park M, Hsu CY, Go AS, et al. Relation of Cigarette Smoking and Heart Failure in Adults ≥65 Years of Age (From the Cardiovascular Health Study). *Am J Cardiol.* 2022;168:90-98.


April 2023 Kaiser Permanente Research Brief: Cardiovascular Disease — 13 —


